Cargando…
The quest for the optimal biomarker: is extending the spectrum of targeted PIK3CA mutations in breast cancer carcinoma worthwhile?
Autores principales: | Quesada, Stanislas, Jacot, William |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632578/ https://www.ncbi.nlm.nih.gov/pubmed/37970606 http://dx.doi.org/10.21037/atm-23-1608 |
Ejemplares similares
-
Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma
por: Rugo, Hope S., et al.
Publicado: (2023) -
Brain Abnormalities in PIK3CA-Related Overgrowth Spectrum: Physician, Patient, and Caregiver Experiences
por: Dexheimer, Joy, et al.
Publicado: (2022) -
Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers
por: Hutchinson, Katherine E., et al.
Publicado: (2023) -
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
por: Martínez-Sáez, Olga, et al.
Publicado: (2020) -
Biomarkers in Routine Heart Failure Clinical Care
por: Nadar, Sunil K, et al.
Publicado: (2019)